Open AccessCase of benralizumab‐induced exacerbations of chronic spontaneous urticaria
Author(s) -
Magen Eli,
Komarova Irina,
Magen Israel,
Phirtskhalava Sofia
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5930
Subject(s) - benralizumab , medicine , immunology , dermatology , intensive care medicine , asthma , mepolizumab , eosinophil
The role of IL‐5 in chronic spontaneous urticarial (CSU) is unclear. It may be that benralizumab is an important bidirectional modifier of CSU; that is, blocking IL‐5 may improve CSU in some patients, but it is possible that it may worsen CSU in others.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom